Publications by authors named "M T Campbell"
Enfortumab vedotin (EV) is used as monotherapy or combined with pembrolizumab in advanced urothelial carcinoma (aUC), but biomarker data associated with EV outcomes are limited. We identified 170 patients in the UNITE study who received EV monotherapy and had molecular biomarker data available. Outcomes for groups with and without a particular biomarker were compared using logistic regression (unadjusted) for the objective response rate (ORR), and a log-rank test and Cox proportional-hazard models (CPHMs) for progression-free survival (PFS) and overall survival (OS) from EV initiation.
View Article and Find Full Text PDFBackground: In the phase 3 JAVELIN Renal 101 trial (NCT02684006), first-line treatment with avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR) vs sunitinib in patients with advanced renal cell carcinoma (aRCC). We report the final analysis, including the primary analysis of overall survival (OS).
Patients And Methods: Patients with untreated aRCC (any prognostic risk score) were enrolled.
Advances in cellular therapies for children and young adults with solid tumors.
Curr Opin Pediatr
February 2025
Article Synopsis
- Adoptive immunotherapy, particularly through cell therapies like CAR T cells and TCR T cell therapy, shows promise for treating high-risk solid tumors in children and young adults, despite being in early development stages.* -
- Current clinical trials indicate that these cell therapies are generally safe, but challenges remain due to the immunosuppressive environment of tumors, hindering their effectiveness.* -
- Enhancing the understanding of immune cell interactions and tumor behavior, along with improving access to these therapies, are crucial for advancing treatment options and standard practice.*
Purpose: Significant improvements in the prognosis for young patients with Primary Immunodeficiency Diseases (PID) and Autoinflammatory Disorders (AID), which together make up the majority of Inborn Errors of Immunity (IEI), have resulted in the need for optimisation of transition and transfer of care to adult services. Effective transition is crucial to improve health outcomes and treatment compliance among patients. Evaluations of existing transition programmes in European health centres identified the absence of disease-specific transition guidelines for PID and AID, as a challenge to the transition process.
View Article and Find Full Text PDF